Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!

Eur Respir J. 2024 Sep 26;64(3):2401247. doi: 10.1183/13993003.01247-2024. Print 2024 Sep.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Aminophenols* / therapeutic use
  • Benzodioxoles* / therapeutic use
  • Chloride Channel Agonists / therapeutic use
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis* / drug therapy
  • Drug Combinations
  • Humans
  • Indoles* / therapeutic use
  • Pyrazoles* / therapeutic use
  • Pyridines* / therapeutic use
  • Pyrroles / therapeutic use
  • Pyrrolidines
  • Quinolines / therapeutic use
  • Quinolones* / therapeutic use
  • Treatment Outcome

Substances

  • Benzodioxoles
  • Aminophenols
  • Indoles
  • Pyrazoles
  • Quinolones
  • Pyridines
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • elexacaftor
  • Drug Combinations
  • ivacaftor
  • Pyrroles
  • tezacaftor
  • Quinolines
  • Chloride Channel Agonists
  • elexacaftor, ivacaftor, tezacaftor drug combination
  • Pyrrolidines